Happy to be wrong here, but (to me), the results of the EFS represents progress and an achievement that is new to the company. Its not a report at a conference, or a media release of a series of patient outcomes, but a formal trial, and a report that brings a new level of evidence.
While the results are reflective of what is already known (performance compared to competitors results, and also compared to historical control data - actual improvements for the patients them selves) plus some new achievements, it may not be what is needed to spark interest in new buyers (investors) and an improvement in SP.
On the other hand, these results will likely support the next phase of the ongoing investigations that will be needed for progression to the next (hopefully commercialisation) stage.
The current results them self may or may not see a rise in SP, but, the commercial success (and the anticipated rise in SP) will need the results of the current study, so these results are adding 'value' even if not reflected in the SP
Opinion not advice
AVR Price at posting:
$19.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)